Mesenchymal Stem Cell Cryopreservation with Interferon-Gamma

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The preservation of mesenchymal stem cells through cryopreservation often results in altered physiological states that compromise their therapeutic efficacy, leading to susceptibility to apoptosis and reduced immunosuppressive properties when administered in clinical settings.

Innovation Solution

Mixing mesenchymal stem cells with interferon-gamma prior to cryopreservation, followed by controlled cooling and thawing, which can include the use of cryoprotectants like trehalose or poly-L-lysine, to enhance cell survival and immunosuppressive function post-thawing.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of stationary object

If mesenchymal stem cells are cryopreserved using conventional methods, then long-term storage is achieved, but cell survival and immunosuppressive properties are compromised

Engineering Contradiction:

Improvestorage durationVSAvoidcell survival and function

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

Mesenchymal stem cells are pre-treated with interferon-gamma and cryoprotectants before cryopreservation to enhance their resistance to freezing stress and maintain functional properties after thawing

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The chemical composition of the cryopreservation medium is modified by adding interferon-gamma and specific cryoprotectants to optimize cell survival and preserve immunosuppressive capabilities during long-term storage

Inventive Principle:

Principle #35Parameter changes

2Duration of action of stationary object

If mesenchymal stem cells are cryopreserved, then storage is enabled, but susceptibility to apoptosis increases

Engineering Contradiction:

Improvestorage capabilityVSAvoidapoptosis susceptibility

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

Interferon-gamma treatment is applied before cryopreservation to preemptively activate cellular defense mechanisms that protect against apoptosis induced by freezing and thawing processes

Inventive Principle:

Principle #9Preliminary anti-action

3Duration of action of stationary object

If mesenchymal stem cells are cryopreserved, then long-term storage is achieved, but immunosuppressive properties are reduced

Engineering Contradiction:

Improvestorage durationVSAvoidimmunosuppressive function

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

Mesenchymal stem cells are pre-treated with interferon-gamma to enhance and stabilize their immunosuppressive properties before cryopreservation, ensuring functional efficacy is maintained after storage and thawing

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method improves the survival and immunosuppressive capabilities of frozen-thawed mesenchymal stem cells, making them more effective in clinical applications by reducing susceptibility to T-cell mediated lysis and maintaining immunomodulatory functions.

Implementation Method 1

interferon-gamma is bound to cell surface receptors on MSCs contained within a frozen mass of MSCs

Methodology Applied

Scientific EffectReceptor binding: Adsorption

Implementation Method 2

The MSCs are in or mixed with a cryoprotectant prior or during cooling

Methodology Applied

Scientific EffectCryoprotection: Freezing

Data Source

PatentUS20230277599A1Methods of Preserving Mesenchymal Stem Cells

Publication Date: 2023.09.07 CHILDRENS HEALTHCARE OF ATLANTA INC

AI summary

This disclosure relates to methods of preserving mesenchymal stromal/stem cells (MSCs) for use in clinical applications. In certain embodiments, this disclosure relates to methods of preserving MSCs comprising mixing MSCs with interferon-gamma prior to cryopreserving, freezing, or cooling the MSCs to a temperature below zero degrees Celsius.